Compare TIMB & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIMB | ARWR |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 9.6B |
| IPO Year | 1998 | 1993 |
| Metric | TIMB | ARWR |
|---|---|---|
| Price | $19.33 | $69.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $22.75 | ★ $63.70 |
| AVG Volume (30 Days) | 370.1K | ★ 2.7M |
| Earning Date | 02-09-2026 | 02-09-2026 |
| Dividend Yield | ★ 9.87% | N/A |
| EPS Growth | ★ 26.01 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $4,941,546,695.00 | $829,448,000.00 |
| Revenue This Year | $8.00 | N/A |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $12.33 | ★ N/A |
| Revenue Growth | 4.96 | ★ 23258.15 |
| 52 Week Low | $11.32 | $9.57 |
| 52 Week High | $23.88 | $72.36 |
| Indicator | TIMB | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 24.91 | 67.54 |
| Support Level | $19.84 | $68.00 |
| Resistance Level | $20.28 | $71.30 |
| Average True Range (ATR) | 0.32 | 3.44 |
| MACD | -0.15 | -0.65 |
| Stochastic Oscillator | 2.91 | 75.58 |
TIM, which is 67%-owned by Telecom Italia, is the third largest wireless carrier in Brazil, with 62 million subscribers, equal to about 24% of the market. The firm also owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 9 million locations, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand. TIM also resells fiber network access from other providers, including Oi's former infrastructure business V.tal.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.